Quantitative structure–activity relationship modeling for predication of inhibition potencies of imatinib derivatives using SMILES attributes

Chronic myelogenous leukemia (CML) which is resulted from the BCR-ABL tyrosine kinase (TK) chimeric oncoprotein, is a malignant clonal disorder of hematopoietic stem cells. Imatinib is used as an inhibitor of BCR-ABL TK in the treatment of CML patients. The main object of the present manuscript is f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamzehali, Hamideh, Lotfi, Shahram, Ahmadi, Shahin, Kumar, Parvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755126/
https://www.ncbi.nlm.nih.gov/pubmed/36522400
http://dx.doi.org/10.1038/s41598-022-26279-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755126/
https://www.ncbi.nlm.nih.gov/pubmed/36522400
http://dx.doi.org/10.1038/s41598-022-26279-8

Ejemplares similares